Similarly, Fujiki et al. recently reported that the SGLT2 inhibitor empagliflozin reduced the number of ventricular arrhythmias in T2DM patients with an implantable cardioverter-defibrillator [265]. Here, SLC5A2 is linked to type 2 diabetes mellitus.